Balanced news tone
News Sentiment
IMTX sentiment intelligence
Immatics NV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
57 relevant articles
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-2.7% over one week, +3.2% over four weeks, trend inactive, and near fair-value range.
(IMTX) and the Role of Price-Sensitive Allocations
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
79/100 classification
One-week reaction
-2.7%
Price reacting lower
Trend fit
Trend inactive
3.2% over four weeks
Fair value
4.5%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
9
Neutral
41
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Sahm
Direct company coverage
How Investors May Respond To Immatics (IMTX) Advancing Its PRAME Franchise With New ASCO 2026 Data
Immatics (IMTX) presented new data at the 2026 ASCO meeting, showcasing deep, durable responses and manageable safety for its PRAME-targeted cell therapies and bispecifics in various solid tumors. The company is building an integrated PRAME franchise, with one asset already in a
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 13 Jun 2026 20:10
- Source
- Sahm
Finviz
Direct company coverage
IMTX - Immatics N.V Stock Price and Quote
This article provides comprehensive financial data, stock performance metrics, analyst ratings, and recent news headlines for Immatics N.V. (IMTX). It details the company's stock price, market cap, income, sales, and various financial ratios, along with a list of recent events an
- Tone
- Positive 60/100
- Event
- Analyst action
- Published
- 11 Jun 2026 17:10
- Source
- Finviz
Stock Traders Daily
Direct company coverage
The Technical Signals Behind (IMTX) That Institutions Follow
This article analyzes Immatics N.v. (IMTX) through AI models, revealing weak near and mid-term sentiment, potentially challenging a long-term positive outlook. It provides specific institutional trading strategies including position, momentum breakout, and risk hedging, along wit
- Tone
- Negative 39/100
- Event
- Guidance
- Published
- 11 Jun 2026 02:00
- Source
- Stock Traders Daily
GlobeNewswire
Direct company coverage
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 12:00
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 May 2026 13:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Immatics starts dual-target lung cancer trial designed to broaden patient reach
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 May 2026 07:00
- Source
- Stock Titan
Stock Traders Daily
Direct company coverage
Precision Trading with Immatics N.v. (IMTX) Risk Zones
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 31 May 2026 07:00
- Source
- Stock Traders Daily
Simply Wall St.
Direct company coverage
Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 10:59
- Source
- Simply Wall St.
simplywall.st
Direct company coverage
Immatics N.V. (NASDAQ:IMTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
MT Newswires
Direct company coverage
Immatics Q1 Loss Widens, Revenue Falls
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 12 May 2026 11:40
- Source
- MT Newswires
Associated Press
Direct company coverage
Immatics: Q1 Earnings Snapshot
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 11:17
- Source
- Associated Press
GlobeNewswire
Direct company coverage
Immatics Announces First Quarter 2026 Financial Results and Business Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- GlobeNewswire
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 06 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Market source
Direct company coverage
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Mar 2026 07:00
- Source
- Market source
Seeking Alpha
Direct company coverage
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Mar 2026 07:00
- Source
- Seeking Alpha
Seeking Alpha
Direct company coverage
Immatics: PRAME Leader's Transition To Commercial Reality
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Dec 2025 08:00
- Source
- Seeking Alpha
Quiver Quantitative
Direct company coverage
Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 05 Dec 2025 08:00
- Source
- Quiver Quantitative
Stock Titan
Direct company coverage
Immatics N.V (IMTX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 01:22
- Source
- Stock Titan
TradingView
Direct company coverage
IMTX Stock Price and Chart — NASDAQ:IMTX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Sep 2023 07:00
- Source
- TradingView
MarketBeat
Direct company coverage
Immatics (IMTX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jul 2020 15:55
- Source
- MarketBeat